NEUROCUPLE™ som et opioidalternativ etter total kneproteseoperasjon
Rollen til NEUROCUPLE™ som et alternativ til opioider hos pasienter etter total kneprotesekirurgi
The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults.
The main questions it aims to answer are:
- Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours after TKA?
- Does the NEUROCUPLE device reduce opioid consumption during the first 24 hours after TKA?
Researchers will compare the NEUROCUPLE device to a placebo device (identical in appearance but inactive) to see if the device reduces pain and opioid use after surgery.
Participants will:
- Apply the NEUROCUPLE device or placebo device for 7 days following surgery
- Have their pain and opioid use monitored through clinical records and patient reporting
- Report pain at rest and during movement on postoperative Days 2 and 7
- Be assessed for nausea, vomiting, device-related side effects, length of hospital stay, and overall satisfaction
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Jacques E. Chelly, MD, PhD, MBA
- Telefonnummer: (412)623-6904
- E-post: ChelJE@anes.upmc.edu
Studer Kontakt Backup
- Navn: Heather Margonari, DNP, FNP, BC
- Telefonnummer: 412-623-1914
- E-post: margonarih@upmc.edu
Studiesteder
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- UPMC Shadyside Hospital
-
Hovedetterforsker:
- Jacques E. Chelly, MD, PhD, MBA
-
Ta kontakt med:
- Heather Margonari,, DNP, FNP-BC
- Telefonnummer: 412-623-1914
- E-post: margonarih@upmc.edu
-
Ta kontakt med:
- Sarah Warner
- E-post: warners3@upmc.edu
-
Pittsburgh, Pennsylvania, Forente stater, 15237
- UPMC Passavant Hospital
-
Hovedetterforsker:
- Jacques E. Chelly, MD, PhD, MBA
-
Pittsburgh, Pennsylvania, Forente stater, 15146
- UPMC East Hospital
-
Hovedetterforsker:
- Jacques E. Chelly, MD, PhD, MBA
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- >18 years of age
- Scheduled for elective primary unilateral TKA
Exclusion Criteria:
- Children (<18 yr.)
- Pregnant women
- Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
- Severe chronic pain condition that requires daily preoperative opioid dependence
- Other concomitant surgery being performed in addition to TKA
- Patients undergoing bilateral TKA
- Patients undergoing knee replacement revision
- Patients with limited mobility (in a wheelchair or requiring a walker)
- Patients who are not returning home after surgery
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: NEUROCUPLE™ Group
This arm of subjects will receive the active NEUROCUPLE™ patch to wear for 7 days following their TKA surgery. |
nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year. The patch will be worn for 7-days Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications |
|
Sham-komparator: Sham Group
This arm of subjects will receive the placebo (non-active, sham) patch to wear for 7 days following their TKA surgery. |
Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications Non-active placebo patch visually identical to NEUROCUPLE™ worn for 7 days following total knee arthroplasty. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Opioid Consumption
Tidsramme: 0- 24 hours post-surgery
|
Total opioid consumption, expressed in milligrams of morphine equivalents (MME), during the first 24 hours following surgery. Opioid use will be calculated using all available data sources, including in-hospital medication administration records and, when applicable, the state Prescription Drug Monitoring Program (PDMP). MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, while higher MME values suggest increased opioid use and potentially greater pain or slower recovery. |
0- 24 hours post-surgery
|
|
Pain at Rest Using Numerical Rating Scale (NRS)
Tidsramme: 0-24 hours post-surgery
|
Pain at rest during the first 24 hours after surgery will be assessed using a Numerical Rating Scale (NRS; 0 = no pain, 10 = worst pain) and compared between the NEUROCUPLE™ patch group and the placebo patch group. Higher scores indicate worse pain |
0-24 hours post-surgery
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Scores Using Numerical Rating Scale (NRS) at Rest and during Movement
Tidsramme: Post-operative at Day 2 and Day 7
|
Pain will be assessed using a Numerical Rating Scale (0 = no pain, 10 = worst pain) at rest and during movement on postoperative Days 2 and 7. Higher scores indicate worse pain. |
Post-operative at Day 2 and Day 7
|
|
Patient Satisfaction
Tidsramme: at Post-operative Day 7
|
Patient satisfaction with recovery and device use will be assessed on postoperative Day 7 using standardized questionnaires. Scores range from 0 to 10, where 0 indicates the lowest level of satisfaction and 10 indicates the highest. |
at Post-operative Day 7
|
|
Opioid Consumption
Tidsramme: Post-Operative Day 0- Day 7
|
Total opioid consumption, expressed in milligrams of morphine equivalents (MME), will be recorded over the 7-day postoperative period. Opioid use will be calculated using all available data sources, including in-hospital medication administration records and the state Prescription Drug Monitoring Program (PDMP) when applicable. MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, whereas higher MME values suggest increased opioid use and potentially greater pain or slower recovery. |
Post-Operative Day 0- Day 7
|
|
Postoperative Adverse Events and Device-Related Side Effects
Tidsramme: Postoperative Days 0-7
|
The incidence of postoperative adverse events, including any events determined to be related to the study device, will be recorded and compared between the treatment groups during the 7-day postoperative period. Lower incidence rates indicate fewer complications and a more favorable safety profile, whereas higher incidence rates suggest increased complications, potential device-related issues, or a less favorable safety profile. |
Postoperative Days 0-7
|
|
Incidence of postoperative nausea and/or vomiting (yes/no)
Tidsramme: Postoperative Days 0-7
|
Incidence and severity of postoperative nausea and vomiting will be recorded over the 7-day postoperative period as (yes/no) and compared between groups. |
Postoperative Days 0-7
|
|
Postoperative Length of Stay
Tidsramme: From the date of surgery until hospital discharge (within the 7-day study period)
|
Length of hospital stay, defined as the number of days from the date of surgery to the date of hospital discharge, will be recorded and compared between groups. Lower length of stay values indicate faster recovery, fewer complications, and earlier readiness for discharge. Higher length of stay values suggest slower recovery, increased complications, or higher postoperative symptom burden. |
From the date of surgery until hospital discharge (within the 7-day study period)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Jacques E. Chelly, MD, PhD, MBA, University of Pittsburgh / UPMC
- Studieleder: Alisha Maslanka, BS, CCRC, University of Pittsburgh / UPMC
- Studieleder: Heather Margonari,, University of Pittsburgh / UPMC
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Smerte
- Nevrologiske manifestasjoner
- Postoperative komplikasjoner
- Patologiske prosesser
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Smerter, postoperativt
- Health Services Administration
- Helsevesenets kvalitet, tilgang og evaluering
- Kirurgiske prosedyrer, operativ
- Kvalitet på helsehjelpen
- Kvalitetsindikatorer, helsehjelp
- Perioperativ omsorg
- Standard for omsorg
- Forbedret bedring etter operasjonen
Andre studie-ID-numre
Andre studie-ID-numre
- STUDY25120065
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .